hrp0084p2-466 | Growth | ESPE2015

Whole Exome Sequencing Identifies De Novo HRAS Mutation Underlying Primary IGF1 Deficiency (PIGFD)

Grosse Greta , Hilger Alina , Draaken Markus , Ludwig Michael , Reutter Heiko , Lorenzen Franziska , Woelfle Joachim

Background: Primary IGF1 deficiency (PIGFD) is a rare condition defined by low IGF1 levels, GH sufficiency and absence of secondary causes of growth failure. PIGFD is an approved indication for treatment with recombinant IGF1 (rIGF1). Its genetic causes remain largely unknown.Objective and hypotheses: To elucidate genetic causes of PIGFD.Method: Clinical phenotyping followed by trio-based whole-exome sequencing (WES) in 11 complete...

hrp0084p3-865 | Fat | ESPE2015

Waist Circumference to Body Height is a Suitable Measure of Cardiovascular Risk in Overweight and Obese Children

Yakovenko Vira , Teufel Ulrike , Henn Laura , Bettendorf Markus , Hoffmann Georg F , Grulich-Henn Juergen

Background: Several methods have been used to evaluate the risk of cardiovascular diseases in obese children. Both BMI and waist-to-hip ratio were suggested as risk factors. However, they did not prove to estimate the risk for cardiovascular events in adulthood. Recent studies suggest that the ratio of waist circumference to body height (WHtR) is a more reliable predictor for cardiovascular risk in 6-10-year old children (Kuba et al. 2013).Objec...

hrp0095p1-521 | Growth and Syndromes | ESPE2022

Case with Hoxa Gene Cluster Delete

Kaya Özdemir Esma , Döğer Esra , Kayhan Gülsüm , Orhun Çamurdan Mahmut , Bideci Aysun

Entrance: HOXA gene deletions cause an appearance characterized by short stature, mild developmental delay, characteristic face, small hands and feet, short and large thumbs, and urogenital malformations. Clinical signs may vary according to the content of the deletion region.Case: The case applied to our clinic with the complaint of short stature. It was learned that the patient was born at term 2500 gr and had bilatera...

hrp0084p3-810 | DSD | ESPE2015

An Atypical Case of Mayer-Rokitansky-Kuster-Hauser Syndrome with Hyperandrogenemia

Ustyol Ala , Atabek Mehmet Emre

Background: Mayer-Rokitansky-Kuster-Hauser syndrome (MRKH) is characterized by utero-vaginal atresia in patients with a normal female phenotype and 46, XX karyotype. Various anomalies may accompany MRKH. The number of cases with accompanying hyperandrogenemia is limited.Case presentation: We describe a combination of Mullerian agenesis and hyperandrogenemia (total testosterone level 0.85 ng/ml) in a patient presenting with primary amenorrhea and mild hir...

hrp0092p1-227 | Growth and Syndromes (to include Turner Syndrome) (1) | ESPE2019

Latest Results From PATRO Children, a Multi-Centre, Observational Study of the Long-Term Safety and Effectiveness of Omnitrope® in Children Requiring Growth Hormone Treatment

Kanumakala Shankar , Pfäffle Roland , Höybye Charlotte , Kriström Berit , Battelino Tadej , Zabransky Markus , Zouater Hichem

Objectives: PATRO Children is an observational, international, longitudinal study of the long-term safety of a recombinant human growth hormone (rhGH; Omnitrope®, Sandoz). In particular, the study will assess the impact of rhGH on glucose metabolism and risk of malignancies. Long-term effectiveness is a secondary objective.Methods: The study population includes infants, children and adolescents receiving ...

hrp0089p2-p326 | Pituitary, Neuroendocrinology and Puberty P2 | ESPE2018

Pituitary Adenomas in Children and Adolescents: A Retrospective Single-Centre Analysis

Breil Thomas , Lorz Catherine , Choukair Daniela , Mittnacht Janna , Inta Ioana , Klose Daniela , Jesser Jessica , Schulze Egbert , Bettendorf Markus

Background: Paediatric pituitary adenomas are rare and mostly benign disorders which may secrete pituitary hormones. Prolactinomas account for half of all pituitary adenomas (PROLA), followed by non-secreting adenomas (20–40%; incidentalomas), adrenocorticotropic-hormone secreting adenomas (10–30%; ACTHA) and growth-hormone-secreting adenomas (5–15%; GHA).Methods: In this single-centre retrospective analysis clinical, biochemical and radio...

hrp0086p1-p99 | Bone & Mineral Metabolism P1 | ESPE2016

Automated Greulich-Pyle Bone Age Determinations in Children with Chronic Endocrine Diseases

Choukair Daniela , Huckmann Annette , Mittnacht Janna , Inta Ioana , Klose Daniela , Schenk Jens Peter , Bettendorf Markus , Thodberg Hans Henrik

Background: Prediction of adult height is a standard procedure in pediatric endocrinology, but it is associated with considerable interrater variability.Objective and hypotheses: To compare the new adult height prediction (PAH) method by automated bone age determination (BoneXpert™) with the conventional PAH method by Bayley Pinneau (BP) based on bone age determination according to Greulich & Pyle. Furthermore, to assess measures of bone health ...

hrp0084p1-118 | Puberty | ESPE2015

Specific Hypothalamic Activation Pattern by mGlu5 Receptor Blockade in vivo During Pubertal Development in Female Mice

Inta Ioana , de Angelis Roberto , Lankisch Katja , Dormann Christof , Pfeiffer Natascha , Boehm Ulrich , Gass Peter , Bettendorf Markus

Background: Puberty is characterised by important changes of brain networks. The glutamate system plays a main role in modulating the onset of puberty as shown for NMDA receptor agonists. However, the underlying mechanisms are poorly understood. Metabotropic mGlu5 receptors (mGluR5) are tightly linked to NMDA receptors. The effect of mGluR5 blockade on neurohormonal mechanisms in puberty initiation were not studied yet.Objective and hypotheses: To invest...

hrp0097p1-28 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Effects of romosozumab on bone ultrastructure and density in a patient with primary osteoporosis caused by a novel heterozygous WNT1 mutation

Montero-Lopez Rodrigo , Blaschitz Alexandra , Tischlinger Katharina , Wimleitner Marlene , Hörtenhuber Thomas , Klinger Markus , Cejka Daniel , Högler Wolfgang

Background: Genetic defects in the Wnt signaling pathway lead to early-onset osteoporosis (EOOP). Romosozumab is a monoclonal antibody against sclerostin, an inhibitor of the Wnt/ß-catenin pathway. Romosozumab has shown great efficacy in adult osteoporosis, however its effect in patients with Wnt-related EOOP is unknown. In monoallelic loss-of-function WNT1 mutations, romosozumab could potentially stimulate the defective Wnt signaling pathway an...

hrp0095p1-279 | Fat, Metabolism and Obesity | ESPE2022

Sex-specific POMC DNA methylation variability is associated with increased body weight

Lechner Lara , Wiegand Susanna , Leitão Elsa , Schröder Christopher , Jöckel Karl-Heinz , Nöthen Markus , Schmidt Börge , Horsthemke Bernhardt , Kühnen Peter

The increasing prevalence of obesity and associated comorbidities worldwide is a major problem for national health care systems. For this reason, it is of importance to gain knew knowledge about the central regulation of body weight and to identify factors which are leading to an increased individual risk to gain weight. Despite large genome weight associations studies and related genetic risk scores, the regulation of inter-individual body weight variability remains elusive. ...